The exploratory analysis by treatment subgroups suggests that the positive effect on PFS of high KRAS4A quantification seems dominant in patients with high (≥ 50%) PD-L1 tumor expression and therefore treated with single-agent Pembrolizumab. This evidence concerns the gene CD274 and neoplasm.